Reply to: ‘Comment on: ‘One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration’
Crossref DOI link: https://doi.org/10.1038/eye.2017.212
Published Online: 2017-10-20
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Almuhtaseb, H
Lotery, A http://orcid.org/0000-0001-5541-4305
Text and Data Mining valid from 2017-10-20
Article History
First Online: 20 October 2017
Competing interests
: HA and AL have received travel support to educational meetings from Bayer Pharmaceuticals.